185 related articles for article (PubMed ID: 9123201)
1. Immunomodulation with intrathymic injection of donor splenocytes followed by CTLA4Ig therapy prolongs small intestinal allograft survival.
Greenstein SM; Sun S; Schechner RS; Tellis VA
Transplant Proc; 1997; 29(1-2):1065-6. PubMed ID: 9123201
[No Abstract] [Full Text] [Related]
2. Review of CTLA4Ig use for allograft immunosuppression.
Lin H; Wei RQ; Gordon D; Linsley P; Turka LA; Bolling SF
Transplant Proc; 1994 Dec; 26(6):3200-1. PubMed ID: 7998114
[No Abstract] [Full Text] [Related]
3. Prolonged small bowel allograft survival following repeated intrathymic injections of donor splenocytes and peripheral anti-lymphocyte treatment.
Sun S; Greenstein SM; Schechner RS; Tellis VA
Transplant Proc; 1999; 31(1-2):588-9. PubMed ID: 10083249
[No Abstract] [Full Text] [Related]
4. Donor intrathymic injection with recipient splenocytes allows indefinite survival following small bowel transplantation in a rat graft-vs-host disease model.
Blakely ML; Shaffer D; Ohzato H; Gottschalk R; Van der Werf WJ; Monaco AP
Transplant Proc; 1994 Jun; 26(3):1582. PubMed ID: 8030046
[No Abstract] [Full Text] [Related]
5. Prolongation of rat small bowel allograft survival by CTLA-4 IG.
Tarumi K; Yagihashi A; Murakami M; Uede T; Hirata K
Transplant Proc; 1998 Sep; 30(6):2596-9. PubMed ID: 9745507
[No Abstract] [Full Text] [Related]
6. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion.
Lin H; Bolling SF; Linsley PS; Wei RQ; Gordon D; Thompson CB; Turka LA
J Exp Med; 1993 Nov; 178(5):1801-6. PubMed ID: 8228826
[TBL] [Abstract][Full Text] [Related]
7. Tolerance for graft-versus-host disease by intrathymic injection of recipient-type splenocytes into donor.
Vaidya S; Wang CC; Roorda C; Billings A; Rajaraman S; Fish JC
Transplant Proc; 1997; 29(1-2):1073-5. PubMed ID: 9123205
[No Abstract] [Full Text] [Related]
8. CD28-B7 T-cell co-stimulatory blockade potentiates the effects of intrathymic immunomodulation in sensitized graft recipients.
Stadlbauer TH; Schaub M; Korom S; Onodera K; Sayegh MH; Kupiec-Weglinski JW
Transplantation; 1997 Dec; 64(12):1816-22. PubMed ID: 9422425
[TBL] [Abstract][Full Text] [Related]
9. Induction and maintenance of tolerance by CTLA-4IG in rat small bowel allografts.
Tarumi K; Yagihashi A; Tsuruma T; Koide S; Sasaki K; Hirata K
Transplant Proc; 1999; 31(1-2):878-81. PubMed ID: 10083385
[No Abstract] [Full Text] [Related]
10. Feasibility of immunosuppression in composite tissue allografts by systemic administration of CTLA4Ig.
Iwasaki N; Gohda T; Yoshioka C; Murakami M; Inobe M; Minami A; Uede T
Transplantation; 2002 Feb; 73(3):334-40. PubMed ID: 11884927
[TBL] [Abstract][Full Text] [Related]
11. CD28 blockade alters cytokine mRNA profiles in cardiac transplantation.
Lin H; Wei RQ; Goodman RE; Bolling SF
Surgery; 1997 Aug; 122(2):129-37. PubMed ID: 9288115
[TBL] [Abstract][Full Text] [Related]
12. Prolonged rat cardiac allograft survival using adenoviral vector containing the CTLA4Ig gene.
Kita Y; Li XK; Hayashi S; Funeshima N; Enosawa S; Tamura A; Suzuki K; Kazui T; Amemiya H; Suzuki S
Transplant Proc; 1998 Jun; 30(4):1079-80. PubMed ID: 9636437
[No Abstract] [Full Text] [Related]
13. A second intrathymic injection of donor splenocytes improves survival of small bowel allografts.
Sun S; Greenstein SM; Kim DY; Schreiber TC; Schechner RS; Tellis VA
Transplant Proc; 1998 Sep; 30(6):2575-6. PubMed ID: 9745495
[No Abstract] [Full Text] [Related]
14. CD28-pathway blockade with CTLA4Ig leads to prolongation of small bowel transplant survival in rats.
Pescovitz MD; Yang R; Liu Q; Collins MH; Grosfeld JL
Transplant Proc; 1994 Jun; 26(3):1618-9. PubMed ID: 8030059
[No Abstract] [Full Text] [Related]
15. Adenoviral vectors containing the CTLA4IG-gene inhibit chronic rejection in heterotopically transplanted rat tracheas.
Kita Y; Li XK; Ohba M; Funeshima N; Enosawa S; Nogimura H; Ohi S; Kageyama Y; Matsushita K; Ito Y; Takahashi T; Suzuki K; Suzuki S; Kazui T
Transplant Proc; 2000 Nov; 32(7):2036-7. PubMed ID: 11120055
[No Abstract] [Full Text] [Related]
16. CTLA-4IG treatment induces long-term acceptance of rat small bowel allografts.
Tarumi K; Yagihashi A; Tsuruma T; Araya J; Hirata K
Transplant Proc; 2000 Nov; 32(7):2028-31. PubMed ID: 11120051
[No Abstract] [Full Text] [Related]
17. Administration of CTLA4-Ig enhances the incidence of hamster-to-rat xenogeneic bone marrow engraftment and alters the presentation of graft-vs-host disease.
Lee YH; Miki T; Kuddus R; Tandin A; Goller AL; Subbotin V; Fung JJ; Peach R; Valdivia LA; Rao AS
Transplant Proc; 2000 Aug; 32(5):1032-3. PubMed ID: 10936336
[No Abstract] [Full Text] [Related]
18. CTLA4-Ig treatment prolongs rat orthotopic liver graft survival.
Tu Y; Rehman A; Flye MW
Transplant Proc; 1997; 29(1-2):1036-7. PubMed ID: 9123186
[No Abstract] [Full Text] [Related]
19. Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion.
Murase N; Ye Q; Lee RG; Demetris AJ; Abu-Elmagd K; Reyes J; Starzl TE
Transplant Proc; 1999; 31(1-2):565-6. PubMed ID: 10083238
[No Abstract] [Full Text] [Related]
20. Indefinite survival following small intestinal transplantation after intrathymic injection of the donor with recipient-type splenocytes in a rat model.
Blakely ML; Shaffer D; Ohzato H; Gottschalk R; Van der Werf WJ; Monaco AP
Transplantation; 1995 Jan; 59(2):309-11. PubMed ID: 7839457
[No Abstract] [Full Text] [Related]
[Next] [New Search]
